NF-kappaB is a critical regulator of the survival of rodent and human hepatic myofibroblasts
- PMID: 18279996
- DOI: 10.1016/j.jhep.2007.12.019
NF-kappaB is a critical regulator of the survival of rodent and human hepatic myofibroblasts
Abstract
Background/aims: Hepatic myofibroblast activation during injury causes deposition of extracellular matrix within the liver and promotes development of fibrosis. Hepatic myofibroblast apoptosis is associated with remodelling of fibrotic extracellular matrix and regression of fibrosis. Previous work showed that inhibition of constitutive NF-kappaB signaling promotes hepatic myofibroblast apoptosis and resolution of fibrosis in rodent models. However, to date agents used to target constitutive NF-kappaB transcriptional activity in hepatic myofibroblasts have been relatively non-specific with potential for off-target effects that may complicate data interpretation. Likewise, rat chronic liver disease models may not accurately recapitulate the activation of human hepatic myofibroblasts.
Methods: We used a mutant recombinant IkappaBalpha super-repressor fused to the HIV-TAT domain to specifically target NF-kappaB signaling in hepatic myofibroblasts. Inhibition of NF-kappaB activity was measured using reporter assay. Apoptosis of hepatic myofibroblasts was assessed by morphological changes, cleavage of the PARP-1 protein and Caspase 3 activation.
Results: TAT-IkappaBalphaSR reduced NF-kappaB dependent transcription, Bcl-2 expression and promoted Jun-N-terminal kinase-dependent apoptosis in human and rat hepatic myofibroblasts.
Conclusions: These data highlight the conserved role of NF-kappaB during fibrogenesis. Our data validate the use of rodent models for pre-clinical testing of NF-kappaB inhibitors as anti-fibrotics and stimulators of fibrotic extracellular matrix remodelling.
Similar articles
-
Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression.Cells. 2021 Oct 15;10(10):2759. doi: 10.3390/cells10102759. Cells. 2021. PMID: 34685739 Free PMC article. Review.
-
What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis.J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2(Suppl 2):65-8. doi: 10.1111/j.1440-1746.2011.07002.x. J Gastroenterol Hepatol. 2012. PMID: 22320919 Free PMC article. Review.
-
Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis.Gastroenterology. 2009 Jun;136(7):2334-2344.e1. doi: 10.1053/j.gastro.2009.02.081. Epub 2009 Mar 18. Gastroenterology. 2009. PMID: 19303015
-
Bakuchiol-induced caspase-3-dependent apoptosis occurs through c-Jun NH2-terminal kinase-mediated mitochondrial translocation of Bax in rat liver myofibroblasts.Eur J Pharmacol. 2007 Mar 22;559(2-3):115-23. doi: 10.1016/j.ejphar.2007.01.024. Epub 2007 Jan 23. Eur J Pharmacol. 2007. PMID: 17292878
-
Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis.Am J Pathol. 2005 Apr;166(4):1017-28. doi: 10.1016/S0002-9440(10)62323-1. Am J Pathol. 2005. PMID: 15793283 Free PMC article.
Cited by
-
Promotion of myofibroblast differentiation through repeated treatment of fibroblasts to low concentrations of PM2.5.Environ Toxicol Pharmacol. 2024 Jan;105:104329. doi: 10.1016/j.etap.2023.104329. Epub 2023 Nov 28. Environ Toxicol Pharmacol. 2024. PMID: 38036232 Free PMC article.
-
AMPK signaling inhibits the differentiation of myofibroblasts: impact on age-related tissue fibrosis and degeneration.Biogerontology. 2024 Feb;25(1):83-106. doi: 10.1007/s10522-023-10072-9. Epub 2023 Nov 2. Biogerontology. 2024. PMID: 37917219 Free PMC article. Review.
-
p53 and Myofibroblast Apoptosis in Organ Fibrosis.Int J Mol Sci. 2023 Apr 4;24(7):6737. doi: 10.3390/ijms24076737. Int J Mol Sci. 2023. PMID: 37047710 Free PMC article. Review.
-
Endotoxemia and Gastrointestinal Cancers: Insight into the Mechanisms Underlying a Dangerous Relationship.Microorganisms. 2023 Jan 19;11(2):267. doi: 10.3390/microorganisms11020267. Microorganisms. 2023. PMID: 36838231 Free PMC article. Review.
-
Anti-fibrotic treatments for chronic liver diseases: The present and the future.Clin Mol Hepatol. 2021 Jul;27(3):413-424. doi: 10.3350/cmh.2020.0187. Epub 2020 Dec 3. Clin Mol Hepatol. 2021. PMID: 33317250 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous